A study by Atlantic White Shark Conservancy, UMass Dartmouth and the Massachusetts Division of Marine Fisheries estimated that 800 white sharks visited the waters off of Cape Cod between 2015 and 2018 ...

Alabama is making waves as it moves to become the first state in the U.S. with an Amber Alert-style system for shark attacks, after the state Senate unanimously passed legislation on Thursday.

The sequel to Fairy Tail, Fairy Tail: 100 Year Quest, continues. Natsu, Lucy, and their guildmates face new challenges. They battle ancient dragons and confront mysterious forces. Season 2 will ...

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced some great news today, which is that it would be acquired by Novartis AG (NVS) for $7 per share in cash. However, there is room for additional ...

KANSAS CITY, Mo. — Dreaming of landing a deal with a Shark? Now’s your chance. Shark Tank has announced an open casting call in Overland Park for entrepreneurs who want to pitch their business ...

TL;DR: She's hooked. Along with offering both red and blue light, the Shark mask also touts infrared LEDs. (Research shows that infrared light can help improve skin texture and tone.) The mask has ...

Novartis (NYSE:NVS) has agreed to acquire biopharmaceutical firm Regulus Therapeutics (NASDAQ:RGLS) for an initial payment of $7.00 a share in cash at closing, or $0.8B. The upfront cash portion ...

Rep. Alexandria Ocasio-Cortez would "destroy America" as president – but is a first-rate entrepreneur – says Canadian businessman and star of ABC's "Shark Tank" Kevin O'Leary. O'Leary's ...

Novartis NOVN0.71%increase; green up pointing triangle has agreed to acquire Regulus Therapeutics RGLS-0.38%decrease; red down pointing triangle for a total equity value of up to roughly $1.7 billion.

Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash upfront through a subsidiary ...

(RTTNews) - Regulus Therapeutics (RGLS) has entered into an agreement and plan of merger with Novartis AG and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will ...

Novartis' established global development and commercial capabilities will enable this important new medicine to reach patients if approved," said Jay Hagan, CEO of Regulus Therapeutics.